Ovid Therapeutics (OVID) Change in Account Payables (2016 - 2026)

Ovid Therapeutics has reported Change in Account Payables for 11 years, with the latest figure at $3.6 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Account Payables rose 391.79% year-over-year to $3.6 million; the trailing twelve-month figure through Mar 2026 stood at $3.6 million (up 320.52% YoY), and the FY2025 full-year result was -$1.2 million, down 141.02% from the prior year.
• Change in Account Payables for Q1 2026 stood at $3.6 million, up from $246000.0 in the prior quarter.
• The five-year high for Change in Account Payables was $3.6 million in Q1 2026, with the low at -$4.9 million in Q1 2022.
• Historically, Change in Account Payables has averaged -$90949.2 across 5 years, with a median of $246000.0 in 2025.
• Annual changes were most pronounced in 2022 — Change in Account Payables soared 718.54% — and 2025, when it sank 1060.75%.
• Ovid Therapeutics' Change in Account Payables stood at $919844.0 in 2022, then soared by 170.26% to $2.5 million in 2023, then slumped by 80.65% to $481000.0 in 2024, then sank by 48.86% to $246000.0 in 2025, then surged by 1373.17% to $3.6 million in 2026.
• The last three Change in Account Payables figures came in at $3.6 million (Q1 2026), $246000.0 (Q4 2025), and -$2.2 million (Q3 2025), per Business Quant data.